Jeffrey is from Washington State, attending the University of Washington for undergraduate. There he joined the laboratory of Charles Chavkin, studying opioid pharmacology. He subsequently matriculated in Duke University’s MD/PhD program, studying chemokine receptor signaling and biased agonism under the mentorship of Sudar Rajagopal and Robert Lefkowitz. After completing a medicine intern year, Jeffrey completed residency in the Harvard Combined Dermatology Residency Program. He joined the Kruse Lab in 2022 and is studying noncanonical GPCR signaling. He is also an attending at the Brigham and Women’s Hospital where he cares for patients with autoimmune skin diseases.